Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Symtuza

- PMLiVE

J&J’s new Darzalex formulation OK’d for use in Europe

Extends use of multiple myeloma therapy even further

- PMLiVE

J&J catches up to Merck, files Ebola vaccine in Europe

Company is also in discussion with the FDA in the US to support regulatory filings

- PMLiVE

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

- PMLiVE

Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis

- PMLiVE

J&J pledges $500m investment into HIV and tuberculosis R&D

Aims to help eliminate both diseases by 2030

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

ViiV builds case for switching to its two-drug HIV combinations

Taking aim at rival Biktarvy

- PMLiVE

Dovato approval key for Glaxo in HIV treatment

First single tablet for treatment-naïve patients

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

GSK, J&J say monthly injection keeps HIV controlled

The once every four-week treatment could free those from taking daily pills

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links